Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study.
APA
Shiota M, Enokida H, et al. (2026). Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study.. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-026-07807-4
MLA
Shiota M, et al.. "Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study.." European journal of nuclear medicine and molecular imaging, 2026.
PMID
41665676
같은 제1저자의 인용 많은 논문 (5)
- Circulating Tumor DNA Genomic Profiling in Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.
- Prediction of Contralateral Lymph Node Involvement during Extended Pelvic Lymph Node Dissection for Clinically Unilateral Prostate Cancer.
- Real-World Treatment Patterns Before and After Metastatic Castration-Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital-Based, Multicenter Database.
- Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.
- ASO Author Reflections: Predictive Factor for Contralateral Lymph Node Involvement in Clinically Unilateral Prostate Cancer.